세계 머릿니 치료 시장 – 2023-2030

Global Lice Treatment Market - 2023-2030

상품코드PH6771
발행기관DataM Intelligence
발행일2023.09.06
페이지 수186 Pages
포맷PDF + EXCEL
커버리지Global

6,525,00011,775,000

보고서 요약(국문)

개요
전 세계 머릿니 치료 시장은 2022년 0.1억 달러 규모에 도달했으며, 2023년부터 2030년까지 연평균 6.3%의 성장률을 보이며 2030년에는 0.2억 달러에 이를 것으로 예상됩니다.
머릿니는 일반적으로 옷, 모자, 스카프, 빗, 브러시, 이발기, 헬멧 등을 함께 사용하는 것을 통해 아이들 사이에서 전염됩니다. 또한 접촉 스포츠를 통해서도 전염될 수 있습니다. 머릿니는 두피 근처, 특히 목덜미와 귀 뒤쪽의 모근에 작고 하얀 알을 낳습니다.
치료 후에는 다른 사람이 돋보기와 밝은 조명을 사용하여 머릿니와 서캐가 있는지 확인해야 합니다. 치료는 일반적으로 활성 감염이 진단된 사람, 즉 모든 가족 구성원과 밀접 접촉자에게 권장됩니다. 활성 감염자와 같은 침대를 사용하는 사람에게는 예방적 치료가 권장됩니다. 감염된 모든 사람과 그들의 침대 동반자는 동시에 치료해야 합니다. 보조적인 조치는 약물 치료와 병행할 수 있지만, 일반적으로 머릿니 감염을 완전히 제거하는 데 필수적인 것은 아닙니다.
또한, 전 세계 머릿니 치료 시장은 첨단 기술 개발에 대한 투자 증가, 신흥 시장의 증가, 연구 개발 투자 증가, Alliance Pharmaceuticals, Omega Pharma(Perrigo Company), Prestige Brands Holdings Inc, Johnson & Johnson Private Limited 등과 같은 주요 기업들의 치료 옵션 발전 등 다양한 요인에 의해 주도되고 있습니다.
시장 동향
머릿니 감염률 증가
머릿니 감염률 증가는 예측 기간 동안 시장 성장을 견인하는 주요 요인 중 하나입니다. 머릿니(Pediculosis capitis) 감염은 흔한 건강 문제이며, 사람의 두피에만 기생하는 기생충인 사람머릿니(Pediculus humanus capitis)에 의해 발생하는 감염성 질환입니다.

예를 들어, 미국 국립 의학 도서관의 Health Equity에서 발표한 기사에 따르면 브라질의 저소득 농촌 지역과 도시 빈민가에서 머릿니 감염률은 각각 28%와 43%로 추정됩니다. 특히 어린이들이 가장 큰 영향을 받으며, 학교 내에서 집단 감염이 발생하는 경우가 많습니다. 저희는 머릿니와 관련된 사회적 낙인을 해소하기 위해 과학적 정보와 지역 전통 치료법을 활용하여 자원이 부족한 지역 사회의 머릿니 감염률을 낮추는 프로그램을 시작했습니다.
규제 당국의 제품 승인 증가
규제 당국의 제품 승인은 머릿니 치료 시장에서 중요한 역할을 합니다. 머릿니 치료 제품은 효능, 품질 및 라벨링을 확인하기 위해 규제 당국의 승인을 받아야 하기 때문입니다. 따라서 각국의 규제 기관에서 제품 승인이 증가하면 전 세계 머릿니 치료 시장의 성장을 견인할 수 있습니다. 예를 들어, 2022년 4월, 아보 파마슈티컬스(Azurity Pharmaceuticals, Inc.의 자회사)는 천연 성분을 함유하여 모발과 두피에서 이와 알을 안전하게 제거하는 혁신적인 헤어 케어 기술에 대한 특허를 미국과 캐나다에서 출원했습니다.
신제품 출시 증가
신제품 출시로 인해 예측 기간 동안 이 시장이 성장하는 데 중요한 역할을 합니다. 새로운 제품 출시를 통해 개선된 제형과 빠른 전달 메커니즘이 개발되어 치료 합병증을 줄일 수 있기 때문입니다. 예를 들어, 2023년 6월 21일, 인도에 본사를 둔 모발 및 두피 치료제 제조업체인 초즌 바이 더마톨로지(Chosen by Dermatology)는 식물 성분이 풍부한 헤어 세럼인 차일드 플레이(Child's Play)를 출시했습니다. 이 제품은 씻어내는 방식으로 이와 서캐를 제거하는 데 사용할 수 있습니다.
어린이 인구 증가 또한 이 치료제 시장 점유율 성장을 뒷받침하는 요인입니다.
전 세계적으로 어린이 인구가 증가함에 따라 예측 기간 동안 이 치료제에 대한 수요가 증가할 것으로 예상됩니다. 어린이는 성인에 비해 개인 공간과 위생 관리에 소홀하기 때문에 머릿니 감염에 더 취약합니다. 전 세계적으로 인구가 급증하고 있어 어린이 인구 증가가 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 특히 유목민 지역의 어린이들은 위생 상태와 머릿니 감염에 대한 인식이 부족하여 도시 및 농촌 지역 어린이들에 비해 머릿니 감염률이 현저히 높습니다.
머릿니 치료 관련 부작용
머릿니 치료의 부작용은 예측 기간 동안 시장 성장을 저해하는 요인 중 하나입니다. 예를 들어, 머릿니 감염 시 가려움, 부기, 발적 등의 두피 자극이 발생할 수 있으며, 퍼메트린 치료 후 일시적으로 악화될 수 있습니다.
또한, 머릿니 감염에 대한 사람들의 인식 부족도 전 세계 머릿니 치료 시장 성장을 저해하는 요인으로 작용할 것으로 예상됩니다. 예를 들어, 머릿니 치료에 대한 가족들의 인식 부족은 종종 살충제나 등유와 같은 전통적인 치료법을 직접 사용하게 만드는데, 이는 매우 위험할 수 있으며 궁극적으로 치료받는 사람의 사망으로 이어질 수 있습니다.
세분화 분석
세계 머릿니 치료 시장은 유형, 약물, 유통 채널 및 지역별로 세분화됩니다.
약물 부문 중 퍼메트린 부문은 머릿니 치료 시장 점유율의 약 41.7%를 차지했습니다.
약물 부문 중 퍼메트린 부문은 41.7%를 차지하며 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 퍼메트린은 성인과 생후 2개월 이상 어린이의 옴을 치료합니다. 일반의약품으로 판매되는 퍼메트린은 성인과 생후 2개월 이상 어린이의 머릿니(머리 피부에 붙는 작은 곤충) 치료에 사용됩니다. 퍼메트린은 옴 및 살충제 계열의 약물로, 머릿니와 진드기를 효과적으로 박멸합니다.

또한, 2022년 5월 NCBI에 따르면 퍼메트린은 머릿니 감염에 대한 일반적인 1차 치료제이며, 많은 국가에서 처방전 없이 구입할 수 있습니다. 머릿니 치료제를 평가한 임상 시험에 대한 체계적인 검토 결과, 퍼메트린이 매우 효과적인 것으로 나타났습니다.
또한, 병원 및 클리닉 부문이 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 예를 들어, 2023년 8월 헤어라인 인터내셔널 헤어 앤 스킨 클리닉은 인도 최초의 머릿니 전문 클리닉을 개설했습니다. 부모와 아이들 모두에게 흔한 걱거리인 머릿니는 치료하지 않고 방치할 경우 두피 가려움증과 세균 감염을 유발할 수 있습니다. 이는 감염된 사람과 부모 모두에게 고통을 줄 수 있습니다.

지리적 시장 침투
북미, 시장 점유율 약 38.6% 차지
북미는 예측 기간 동안 전체 시장 점유율의 약 38.6%를 차지할 것으로 예상됩니다. 이는 어린이의 이 감염률이 높고, 제품 혁신, 선진 의료 인프라, 무화학 제품에 대한 수요 증가, 그리고 다른 지역에 비해 앞선 기술력을 보유하고 있다는 점에 기인합니다. 이러한 요소들이 북미 지역의 성장을 견인할 것으로 전망됩니다.
예를 들어, 2021년 8월, 전문 제약 회사인 ParaPRO는 30년 만에 FDA 승인을 받은 최초의 옴 치료제 신약인 Natroba(스피노사드) 국소 현탁액 0.9%를 출시했습니다. 이 제품은 4세 이상 소아 및 성인의 옴 감염에 대한 최초의 국소 치료제입니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Alliance Pharmaceuticals, Omega Pharma(Perrigo Company), Prestige Brands Holdings Inc., Johnson & Johnson Private Limited, Fleming Medical Ltd, RID Lice(Oystershell Consumer Health, Inc), Nisarg Pharma, ParaPRO Pharmaceuticals, ICB Pharma, Marico 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 머릿니 치료 시장에 여러 가지 영향을 미쳤으며, 특히 검사 대상 아동 집단에서 머릿니 감염률이 증가했습니다. 그러나 봉쇄 기간 동안 아동들을 소규모 그룹으로 나누거나 부모의 관심이 증가한 것과 같은 요인이 COVID-19 발생 이전 기간 대비 감염률 감소에 기여했는지 여부는 불분명합니다.
따라서 COVID-19로 인해 필수품 부족과 여러 어려움이 발생했지만, 머릿니 치료는 COVID-19 기간 동안 중요한 역할을 했습니다. 이처럼 COVID-19 팬데믹은 초기에는 해당 시장의 성장에 영향을 미쳤지만, 현재는 회복세를 보이고 있습니다. 예측 기간 동안 꾸준한 성장이 예상됩니다.
유형별
• 머릿니(두부 이)
• 머릿니(체부 이)
• 머릿니(음모 이)
의약품별
• 일반의약품
o 퍼메트린
o 피레트린
o 기타 제품 유형
• 전문의약품
o 이버멕틴
o 스피노사드
o 말라티온
유통 채널별
• 병원 및 클리닉
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
 2022년 10월, 얼라이언스 파마슈티컬스는 사우스 플로리다 가족 건강 및 연구 센터와 협력하여 Vamousse Spray의 안전성과 효능을 확인하기 위한 임상 시험을 clinicaltrials.gov에 게시했습니다. 'n' Go는 1% 퍼메트린 대조군 샴푸와 비교했을 때 머릿니 치료에 효과적입니다.
 2022년 9월, 미국 소아과학회는 머릿니 진단 및 치료에 대한 최신 지침을 발표했습니다. 새로운 치료제도 언급되었으며, 감염 환자 관리 알고리즘과 진단 및 치료에 대한 추가 설명도 제공되었습니다.

2021년 10월, 라이스 클리닉스 오브 아메리카(Lice Clinics of America)는 온풍을 이용한 머릿니 치료 75만 건을 성공적으로 완료했으며, 매우 높은 성공률을 기록했다고 발표했습니다.

보고서 구매 이유:

• 유형, 치료제, 유통 채널 및 지역별 글로벌 머릿니 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 글로벌 머릿니 치료 시장의 다양한 데이터가 담긴 엑셀 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 이 치료제 시장 보고서는 약 61개의 표, 58개의 그림, 186페이지 분량입니다.
2023년 주요 독자층
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Lice Treatment Market reached US$ 0.1 billion in 2022 and is expected to reach US$ 0.2 billion by 2030, growing with a CAGR of 6.3% during the forecast period 2023-2030.
Lice are typically transmitted from child to child through sharing clothing, hats, scarves, combs, brushes, hair trims, or helmets with nits. They can also be passed during contact sports. Head lice lay small white eggs at the base of hair near the scalp, particularly on the back of the neck and behind the ears.
After treatment, the infected person should be checked by another person for lice and nits using a magnifying glass and bright light. Treatment is usually recommended for persons diagnosed with an active infestation, including all household members and close contacts. Prophylactic treatment is advised for those sharing the same bed with actively-infested individuals. All infested persons and their bedmates should be treated simultaneously. Supplemental measures can be combined with pharmacologic treatment, but these are generally not required to eliminate a head lice infestation.
Furthermore, the global lice treatment is driven by various factors like, rising investment for the development of advanced technologies, an increase in the number of emerging markets, a rise in research and development, advancements in treatment options having significant key players like Alliance Pharmaceuticals, Omega Pharma(Perrigo Company), Prestige Brands Holdings Inc, Johnson & Johnson Private Limited and among others.
Dynamics
Rise in the Prevalence of Lice Infestation
The rise in the prevalence of lice infestation is one of the factors to drive the market during the forecast period. Infestation with head lice (Pediculosis capitis) is a common health problem, it is an infectious condition caused by an obligatory ectoparasite, the human louse (Pediculus humanus capitis) and affects only the human scalp.
For instance, according to the article published by Health Equity in the National Library of Medicine, the prevalence of head lice in poor rural communities and urban slums is estimated to be between 28% and 43% in Brazil, respectively. Children are among the most affected, often in clusters within schools. We launched a program intending to tackle the social stigma associated with head lice using scientific information and a local traditional remedy as a way to lower the prevalence of head lice in a low-resource community.
Rise in Product Approvals by Regulatory Authorities
Product approvals by regulatory authorities play an important role in the lice treatment market as lice treatment products required regulatory approvals to check efficacy, quality and labelling. Hence the increasing product approvals by regulatory agencies of respective countries can drive the growth of the global lice treatment market. For instance, in April 2022, Arbor Pharmaceuticals Inc. (A subsidiary of Azurity Pharmaceuticals, Inc.), issued patents in the U.S. and Canada for its novel hair care technology containing all-natural ingredients to dislodge and safely remove lice and eggs from the hair shaft and scalp.
Increase in The Product Launches
Innovation of new products plays an important role to drive this market during the forecast period, as introducing new products creates improved formulations and fast delivery mechanisms which helps in the treatment have fewer complications. For instance, on June 21, 2023, Chosen by Dermatology- an India-based manufacturer of hair and scalp treatments, launched Child's Play, a hair serum with high plant content. The product can be used as a wash-off product when used to treat lice and nits.
Rise in the Population of Children Is Another Factor Supporting the Lice Treatment Market Share Growth
The rising number of children across the globe is expected to raise the demand for lice treatment solutions during the forecast period. Children are more prone to lice infestation as compared to adults, as they are less protective of their personal space and hygiene. There is a rapid rise in population across the globe; hence, the rising number of children is expected to propel market growth during the forecast period. The rising prevalence of lice infestation is also significantly high in children from nomad tribes, as compared to rural and urban areas due to lack of hygiene and awareness regarding lice infestation.
Side Effects Associated With Lice Treatment
Complications of lice treatments are one of the restraints that hamper the market from growth during the forecast period. Some of them are like Scalp irritation, including itching, swelling, or redness may occur with head lice and temporarily worsen after treatment with permethrin.
Also, A lack of awareness among people is expected to hamper the growth of the global lice treatment market. For instance, the lack of awareness of families about treating head lice often leads to the direct use of traditional medicines, including insecticides or kerosene, which can be very harmful and ultimately cause the death of the person being treated.
Segment Analysis
The global lice treatment market is segmented based on type, medication, distribution channel and region.
The Permethrin Segment From The Medication Segment Accounted for Approximately 41.7% of the Lice Treatment Share
The permethrin segment from the medication segment accounted for 41.7% and it is expected to be dominated during the forecast period. Permethrin treats scabies in adults and children two months of age and older. Over-the-counter permethrin is used to treat head lice (tiny insects that attach to the skin on the head) in adults and children two months of age and older. Permethrin is part of a group of medicines called scabies and Insecticides. It's effective in killing lice and mites.
Furthermore, according to NCBI in May 2022, permethrin is a common first-line treatment option for head lice infestations, which is available over the counter in many countries and a systematic review of trials that evaluated medications for the treatment of head lice suggested that permethrin was very much effective.
Also, the hospitals and clinics segment is expected to dominate during the forecast period. For instance, in August 2023 Hairline International Hair and Skin Clinic opened India's first-ever LICE Clinic to combat Head Lice Infestation. Head lice, a common concern among parents and children, can cause scalp itching and potential bacterial infections if left untreated. This can cause distress for affected individuals and parents.
Geographical Penetration
North America Accounted for Approximately 38.6% of the Market Share
North America is estimated to hold about 38.6% of the total market share throughout the forecast period, owing to the high prevalence of lice infestations among children, Product Innovation, advanced healthcare infrastructure, and rise in demand for chemical-free products, moreover, this region is having advanced technologies compared to another region which indeed helps this region to grow during the forecast period.
For instance, in August 2021 ParaPRO, a specialty pharmaceutical company, announced the availability of Natroba (spinosad) Topical Suspension, 0.9%, the first new drug application for scabies approved by the FDA in over 30 years. The product is the first targeted topical treatment for scabies infestations in adult and pediatric patients aged four and older.
Competitive Landscape
The major global players in the market include Alliance Pharmaceuticals, Omega Pharma(Perrigo Company), Prestige Brands Holdings Inc., Johnson & Johnson Private Limited, Fleming Medical Ltd, RID Lice(Oystershell Consumer Health, Inc) Nisarg Pharma, ParaPRO Pharmaceuticals, ICB Pharma, Marico and among others.
COVID-19 Impact Analysis
Covid 19 pandemic had numerous impacts on the lice treatment market where the spread of head lice infestations among the tested groups of children was more. However, it remains unclear whether factors such as the separation of children into smaller groups or increased parental attention during lockdown contributed to the reduction in infestation rates compared to the period before the COVID-19 outbreak.
Thus, although COVID-19 has led to a shortage of essentials and created some hindrances, lice treatment has played an important role during COVID-19. Thus, the COVID-19 pandemic has impacted the growth of the studied market in the initial phase, however, currently; it is expected to have steady growth during the forecast period.
By Type
• Pediculosis Capitis
• Pediculosis Corporis
• Pediculosis Pubis
By Medication
• OTC Medication
o Permethrin
o Pyrethrin
o Other Product Types
• Prescription Medication
o Ivermectin
o Spinosad
o Malathion
By Distribution Channel
• Hospitals and Clinics
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
 In October 2022, Alliance Pharmaceuticals collaborated with South Florida Family Health and Research Centers and posted a clinical trial on clinicaltrials.gov to check the safety and efficacy of Vamousse Spray 'n' Go, compared to a 1% Permethrin control shampoo, in the treatment of head lice.
 In September 2022, the American Academy of Pediatrics updated guidance on diagnosing and treating head lice. New medications for treatment were also mentioned and they provided an algorithm for the management of affected patients and further provided clarification on diagnosis and treatment.
 In October 2021, Lice Clinics of America announced that the company completed 750,000 successful head lice treatments using heated air, with a very high success rate.
Why Purchase the Report?
• To visualize the global lice treatment market segmentation based on type, medication, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global lice treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global lice treatment market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Medication
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the Prevalence of Lice Infestation
4.1.1.2. Rise in Product Approvals by Regulatory Authorities
4.1.1.3. Increase in The Product Launches
4.1.1.4. The Growing Population of Children Is Another Factor Supporting the Lice Treatment Market Share Growth.
4.1.2. Restraints
4.1.2.1. Side Effects Associated with Lice Treatment
4.1.3. Opportunity
4.1.3.1. Rise in Research and Development
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Pediculosis Capitis *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Pediculosis Corporis
7.4. Pediculosis Pubis
8. By Medication
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
8.1.2. Market Attractiveness Index, By Medication
8.2. OTC Medications *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Prescription Medications
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospitals and Clinics *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Russia
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Alliance Pharmaceuticals*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Omega Pharma(Perrigo Company)
12.3. Prestige Brands Holdings Inc.
12.4. Johnson & Johnson Private Limited
12.5. Fleming Medical Ltd
12.6. RID Lice(Oystershell Consumer Health, Inc)
12.7. Nisarg Pharma
12.8. ParaPRO Pharmaceuticals
12.9. ICB Pharma
12.10. Marico
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Alliance Pharmaceuticals, 4. Key Developments, Omega Pharma(Perrigo Company), Prestige Brands Holdings Inc., Johnson & Johnson Private Limited, Fleming Medical Ltd, RID Lice(Oystershell Consumer Health, Inc), Nisarg Pharma, ParaPRO Pharmaceuticals, ICB Pharma, Marico

표 목록 (Tables)

List of Tables

Table 1 Global Lice Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Lice Treatment Market Value, By Medication, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Lice Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Lice Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Lice Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Lice Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 7 Global Lice Treatment Market Value, By Medication, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Lice Treatment Market Value, By Medication, 2021-2030 (US$ Billion)

Table 9 Global Lice Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Lice Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 11 Global Lice Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Lice Treatment Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Lice Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 14 North America Lice Treatment Market Value, By Medication, 2021-2030 (US$ Billion)

Table 15 North America Lice Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 16 North America Lice Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Lice Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 18 South America Lice Treatment Market Value, By Medication, 2021-2030 (US$ Billion)

Table 19 South America Lice Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 20 South America Lice Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Lice Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 Europe Lice Treatment Market Value, By Medication, 2021-2030 (US$ Billion)

Table 23 Europe Lice Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 24 Europe Lice Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Lice Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Lice Treatment Market Value, By Medication, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Lice Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Lice Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East & Africa Lice Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 30 Middle East & Africa Lice Treatment Market Value, By Medication, 2021-2030 (US$ Billion)

Table 31 Middle East & Africa Lice Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 32 Alliance Pharmaceuticals: Overview

Table 33 Alliance Pharmaceuticals: Product Portfolio

Table 34 Alliance Pharmaceuticals: Key Developments

Table 35 Omega Pharma(Perrigo Company): Overview

Table 36 Omega Pharma(Perrigo Company): Product Portfolio

Table 37 Omega Pharma(Perrigo Company): Key Developments

Table 38 Prestige Brands Holdings Inc.: Overview

Table 39 Prestige Brands Holdings Inc.: Product Portfolio

Table 40 Prestige Brands Holdings Inc.: Key Developments

Table 41 Johnson & Johnson Private Limited: Overview

Table 42 Johnson & Johnson Private Limited: Product Portfolio

Table 43 Johnson & Johnson Private Limited: Key Developments

Table 44 Fleming Medical Ltd: Overview

Table 45 Fleming Medical Ltd: Product Portfolio

Table 46 Fleming Medical Ltd: Key Developments

Table 47 RID Lice(Oystershell Consumer Health, Inc): Overview

Table 48 RID Lice(Oystershell Consumer Health, Inc): Product Portfolio

Table 49 RID Lice(Oystershell Consumer Health, Inc): Key Developments

Table 50 Nisarg Pharma: Overview

Table 51 Nisarg Pharma: Product Portfolio

Table 52 Nisarg Pharma: Key Developments

Table 53 ParaPRO Pharmaceuticals: Overview

Table 54 ParaPRO Pharmaceuticals: Product Portfolio

Table 55 ParaPRO Pharmaceuticals: Key Developments

Table 56 ICB Pharma: Overview

Table 57 ICB Pharma: Product Portfolio

Table 58 ICB Pharma: Key Developments

Table 59 Marico: Overview

Table 60 Marico: Product Portfolio

Table 61 Marico: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Lice Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Lice Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 4 Global Lice Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Lice Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Lice Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 7 Pediculosis Capitis Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 8 Pediculosis Corporis Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 9 Pediculosis Pubis Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 10 Global Lice Treatment Market Y-o-Y Growth, By Medication, 2022-2030 (%)

Figure 11 OTC Medications Medication in Global Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 12 Prescription Medications Medication in Global Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 13 Global Lice Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 14 Hospitals and Clinics Distribution Channel in Global Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 15 Retail Pharmacies Distribution Channel in Global Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 17 Online Pharmacies Distribution Channel in Global Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 18 Global Lice Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 19 North America Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 20 Asia-Pacific Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 21 Europe Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 22 South America Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 23 Middle East and Africa Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 24 North America Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 25 North America Lice Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 26 North America Lice Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 27 North America Lice Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 28 North America Lice Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 29 South America Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 30 South America Lice Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 31 South America Lice Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 32 South America Lice Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 33 South America Lice Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 34 Europe Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 35 Europe Lice Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 36 Europe Lice Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 37 Europe Lice Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 38 Europe Lice Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 39 Asia-Pacific Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 40 Asia-Pacific Lice Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 41 Asia-Pacific Lice Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 42 Asia-Pacific Lice Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 43 Asia-Pacific Lice Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 44 Middle East & Africa Lice Treatment Market Value, 2021-2030 (US$ Billion)

Figure 45 Middle East & Africa Lice Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 46 Middle East & Africa Lice Treatment Market Share, By Medication, 2022 & 2030 (%)

Figure 47 Middle East & Africa Lice Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 48 Alliance Pharmaceuticals: Financials

Figure 49 Omega Pharma(Perrigo Company): Financials

Figure 50 Prestige Brands Holdings Inc.: Financials

Figure 51 Johnson & Johnson Private Limited: Financials

Figure 52 Fleming Medical Ltd: Financials

Figure 53 RID Lice(Oystershell Consumer Health, Inc): Financials

Figure 54 Nisarg Pharma: Financials

Figure 55 ParaPRO Pharmaceuticals: Financials

Figure 56 ICB Pharma: Financials

Figure 57 Marico: Financials